 |
||||||||
|
|
|
|
|
|
 |
||||
|
The Brain Trust Accelerator Funds focus on translational stage investments that address the diagnosis and treatment of brain-related diseases. Investments in portfolio companies have generated top tier rates of return, resulted in approaches to benefit up to ten million patients with brain diseases,
and delivered $500,000 to charities.
Brain Trust Accelerator Fund I Portfolio Brain Trust Accelerator Fund II Portfolio Brain Trust Accelerator Fund I Portfolio 
Amnestix Amnestix was an early-stage biotech company founded in 2006, that focused on novel therapeutics for improving memory deficits associated with a variety of human diseases. The company was founded on the discoveries of Dietrich Stephan, PhD, Director of the Neurogenomics Division and his associate, Matthew Huentelman, PhD, at the Translational Genomics Institute in Phoenix, Arizona, along with collaborators at the University of Zurich. Working with Amnestix Chief Executive Officer Karoly Nikolich, PhD, the company was developing small-molecule drugs for memory-related disorders. The sole funding for Amnestix was provided by Brain Trust Accelerator Fund I. Amnestix was successfully acquired in June 2008 by SYGNIS Pharma AG, a leading European biotechnology company. www.sygnis.com 
BrainScope Company, Inc. BrainScope is a neuro-technology company that is pioneering the assessment of brain injury and function, including concussion. The company's innovative BrainScope One system is an easy-to-use, non-invasive, hand-held platform that empowers physicians to make more accurate head injury assessments quickly at the point-of-care. BrainScope One was launched in 2017 and sales are developing in a cross-section of market segments including urgent care clinics, hospital emergency rooms, university and professional sports, and the US military and government. www.brainscope.com 
Chase Pharmaceuticals Corporation Chase Pharmaceuticals was an early-stage pharmaceutical company engaged in the identification and clinical development of medically improved, commercially promising treatments for central nervous system diseases. The company's aim is to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with brain disease. Brain Trust Accelerator Fund I was the sole investor in the Series A financing in 2010. After successful Phase I clinical trials, Chase closed a $21 million Series B financing in 2014 to fund Phase II clinical trials in patients with Alzheimer's disease. The new investors in the Series B round included Edmund de Rothschild Investment Partners, Cipla Ventures and New Rhein Healthcare. After a successful Phase II trial in Alzheimer's patients, the company was acquired by Allergan in 2016. See: Allergan Acquires Chase Pharma 
Neurofluidics, Inc. Neurofluidics was an early-stage medical device company that developed novel, targeted treatment approaches for patients suffering from a variety of serious neurological disorders. Brain Trust Accelerator Fund I was the primary investor in the company. The company was successfully acquired by Minnetronix, a leading medical device company, in June 2013. Minnetronix continues to advance the development of the Neurofluidics unique technology to access and purify the cerebral spinal fluid. www.minnetronix.com 
Satoris Satoris was an early-stage molecular diagnostics company when Brain Trust Accelerator Fund I invested in the firm, which focused on developing blood-based tests for neurodegenerative diseases. The company was developing neurodiagnostic tests that yielded the earliest, most accurate and clinically relevant diagnoses, so that healthcare costs can be reduced while patient care becomes even more effective. Myriad Genetics acquired the Satoris diagnostic technology in 2011 and is continuing development of the blood-based tests. www.myriad.com Brain Trust Accelerator Fund II Portfolio 
NeuroTherapia NeuroTherapia is a clinical stage biotech company developing an orally available, small molecule targeting CB2 receptors on activated microglial cells to reduce neuroinflammation. The company hascompleted its first-in-human, Phase 1a clinical trial, where its lead product, NTRX-07, was shown to be safe, produced blood levels predicted to be efficacious.. NeuroTherapia will continue clinical development of NTRX-07, and next generation molecules in subjects with neurodegenerative diseases, assessing biomarkers to monitor bioactivity following treatment. The targeting of activated microglial through CB2 receptors represents a novel strategy in treating diseases involving neuroinflammation, including AD, ALS, pain and other disorders. www.neurotherapia.com neurotherapia.com
Chase Pharmaceuticals Corporation Chase Pharmaceuticals was an early-stage pharmaceutical company engaged in the identification and clinical development of medically improved, commercially promising treatments for central nervous system diseases. The company's aim is to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with brain disease. Brain Trust Accelerator Fund I was the sole investor in the Series A financing in 2010. After successful Phase I clinical trials, Chase closed a $21 million Series B financing in 2014 to fund Phase II clinical trials in patients with Alzheimer's disease. The new investors in the Series B round included Edmund de Rothschild Investment Partners, Cipla Ventures and New Rhein Healthcare. After a successful Phase II trial in Alzheimer's patients, the company was acquired by Allergan in 2016. Allergan Acquires Chase Pharma Chase Therapeutics Corporation Chase Therapeutics' mission is to revolutionize the treatment of Parkinson's disease and related neurodegenerative diseases. The company was founded by the same management team as Chase Pharmaceuticals; however, their discoveries will be applied to different disease states and will attempt to delay symptom onset and slow disease progression. As the company advances its programs, more information will be made available. |
||||